Polymorphisms in ERCC1, XRCC1 genes and sensitivity to gemcitabine/cisplatin chemotherapy in non-small cell lung cancer

Chinese Journal of Cancer Prevention and Treatment

Volumn 16, Issue 1, 2009, Pages 27-30

  Gao, Chang Ming ^a   Shi, Mei Qi ^a   Wu, Jian Zhong ^a   Cao, Hao Xia ^a   Feng, Ji Feng ^a   Xu, Lin ^a  

^a JIANGSU CANCER HOSPITAL   (China)

Author keywords

Carcinoma; Gene expression; Genetic; Non small cell lung drug therapy; Polymorphism

Indexed keywords

CISPLATIN; DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; XRCC1 PROTEIN;

ADULT; AGED; ARTICLE; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; LEUKOCYTE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 77951542593     PISSN: 16735269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy[J]. Cancer Treat Rev, 1998, 24(5):331-344.
2. Rosell R, Lord R V, Taron M, et al. DNA repair and cisplatin resistance in non-small-cell lung cancer[J]. Lung Cancer, 2002, 38(3):217-227.
3. Lunn R M, Langlois R G, Hsieh L L, et al. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency[J]. Cancer Res, 1999, 59(11):2557-2561.
4. Duell E J, Millikan R C, Pittman G S M, et al. Polymorphisms in the DNA repair gene XRCC1 and breast cancer[J]. Cancer Epidemiol Biomarkers Prev, 2001, 10(3):217-222.
5. Lee S G, Kim B, Choi J, et al. Genetic polymorphisms of XRCC1 and risk of gastric cancer[J]. Cancer Lett, 2002, 187 (1-2):53-60.
6. Cho E Y, Hildesheim A, Chen C J, et al. Nasopharyngeal carcinoma and genetic polymorphisms of DNA repair enzymes XRCC1 and hOGG1 [J]. Cancer Epidemiol Biomarkers Prev, 2003, 12(10):1100-1104.
7. Viguier J, Boige V, Miquel C, et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer[J]. Clin Cancer Res, 2005, 11(17): 6212-6217.
8. Zhou W, Gurubhagavatula S, Liu G, et al. Christianil, excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy[J]. Clin Cancer Res, 2004, 10(15):4939-4943.
9. Chinese source.
10. Chinese source.
11. de-las Peñas R, Sanchez-Ronco M, Alberola V, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients[J]. Ann Oncol, 2006, 17(4):668-675.
12. Park S Y, Hong Y C, Kim J H, et al. Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients[J]. Med Oncol, 2006, 23(4):489-498.
13. Rosell R, Cuello M, Cecere F, et al. Usefulness of predictive tests for cancer treatment[J]. Bull Cancer, 2006, 93(8): E101-108.
14. Su D, Ma S, Liu P, et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer[J]. Lung Cancer, 2007, 56(2):281-288.
15. Chinese source.